Heterocyclic Building Blocks-Pyridazine

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.10344-42-0,4-Bromo-3,6-dichloropyridazine,as a common compound, the synthetic route is as follows.

c) 3,6-Dichloro-4-(3,6-dihydro-2H-pyridin-1-yl)pyridazine 1,2,3,6-Tetrahydropyridine, (1.04 ml) was added to a stirred solution/suspension of 4-bromo-3,6-dichloropyridazine (2.0 g, 8.8 mmol) and potassium carbonate (2.4 g) in dry DMF (10 ml) at room temperature under nitrogen. The mixture was stirred at room temperature for 5 hours. The reaction was poured into water (100 ml) and extracted with ethyl acetate (*3). The combined extracts were washed with water (200 ml), brine, dried (MgSO4), filtered and evaporated. The residue was triturated with ether/petroleum ether to afford a white powder (1.96 g, 97%). 1H NMR (250 MHz, CDCl3) 6.82 (1H, s), 5.97 (1H, m), 5.80 (1H, m), 3.77 (2H, m), 3.59 (2H, m), 2.38 (2H, m). MS (ES+) 232 [MH]+.

10344-42-0 4-Bromo-3,6-dichloropyridazine 22030648, apyridazine compound, is more and more widely used in various.

Reference£º
Patent; Merck Sharp & Dohme Ltd.; US6319924; (2001); B1;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem

89466-38-6, 6-Chloro-3-methoxy-4-methylpyridazine is a pyridazine compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

A solution of 6- chloro-3-methoxy-4-methylpyridazine (3.31 g, 20.9 mmol) in 4:1 dioxane: water (100 mL) was treated with 12.0 M HC1(aq) (1.91 mL, 23.0 mmol) and stirred for 60 h at 60 C. The reaction mixture was concentrated under vacuum, and the resulting crude residue was purified by silica chromatography (1-30% DCMIMeOH with 2% NH4OH as the gradient eluent) to afford the title compound (2.99 g, 99% yield). ?HNMR(400 IVIFIz, DMSO-d6) 13.03 (s, 1H), 7.44 (s, 1H), 2.05 (s, 3H).

The synthetic route of 89466-38-6 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; ARRAY BIOPHARMA, INC.; ANDREWS, Steven W.; BLAKE, James F.; COOK, Adam; GUNAWARDANA, Indrani W.; HUNT, Kevin W.; METCALF, Andrew T.; MORENO, David; REN, Li; TANG, Tony P.; (263 pag.)WO2017/70708; (2017); A1;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1121-79-5,3-Chloro-6-methylpyridazine,as a common compound, the synthetic route is as follows.

Step 1. 3-Chloro-6-chloromethyl-pyridazine To a solution of 3-chloro-6-methyl-pyridazine (25 g, 0.2 mol) in chloroform (850 mL) at 60 C. was added trichloroisocyanuric acid (0.4 eqivalent, 18.1 mol) and stirred for 15 hours. An additional charge of trichloroisocyanuric acid (3 g) was added and the mixture heated for an additional hour. The mixture was then cooled in an ice bath and filtered over celite. The organic solution was concentrated to a yellow oil which darkened and solidified upon standing in the freezer (yield 30 g, 95%).

As the paragraph descriping shows that 1121-79-5 is playing an increasingly important role.

Reference£º
Patent; Leivers, Martin Robert; Lauchli, Ryan; US2010/29655; (2010); A1;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem

65202-50-8, Methyl 6-chloropyridazine-3-carboxylate is a pyridazine compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Methyl 6-chloropyridazine-3-carboxylate (1.4 g), spiro[1-benzofuran-3,3′-pyrrolidine] (1.5 g), potassium carbonate (1.4 g) and tetrabutylammonium iodide (370 mg) were suspended in tetrahydrofuran (80 mL), and the suspension was stirred under reflux overnight. The reaction mixture was diluted with ethyl acetate, and washed with aqueous sodium carbonate solution. The organic layer was dried over sodium sulfate and the solvent was evaporated under reduced pressure. Ethyl acetate-hexane was added and the resulting precipitate was collected by filtration to give the object product (2.2 g, 88%). 1H NMR (300 MHz, DMSO-d6) delta ppm 2.21-2.41 (m, 2H) 3.52-4.04 (m, 7H) 4.43-4.54 (m, 2H) 6.80-7.02 (m, 3H) 7.13-7.25 (m, 1H) 7.32 (d, J=7.35 Hz, 1H) 7.87 (d, J=9.42 Hz, 1 H)

As the paragraph descriping shows that 65202-50-8 is playing an increasingly important role.

Reference£º
Patent; Taniguchi, Takahiko; Miyata, Kenichi; Kubo, Osamu; US2010/69351; (2010); A1;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem

20698-04-8, 3,6-Diiodopyridazine is a pyridazine compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

3-Iodo-6-dimethylaminopyridazine can be prepared by stirring a solution of 3,6-diiodopyridazine (203.7 g) and dimethylamine (276 g) in methanol (1500 cc) at a temperature of about 20 C for 48 hours. After evaporation to dryness under reduced pressure, the residue obtained is stirred for 15 minutes with distilled water (1500 cc). The insoluble product is filtered off and washed with distilled water (2 * 200 cc). 6-Dimethylamino-3-iodopyridazine (113.7 g), melting at 135 C, is obtained.

The synthetic route of 20698-04-8 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Rhone-Poulenc Industries; US4110450; (1978); A;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem

35857-89-7, 6-Chloropyridazine-3-carbonitrile is a pyridazine compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a deoxygenated mixture of 6-chloropyridazine-3-carbonitrile (100 mg, 0.717 mmol) , (4- (methylsulfonyl) phenyl) boronic acid (215 mg, 1.08 mmol) , and sodium carbonate (190 mg, 1.79 mmol) in dioxane (3 mL) and water (0.600 mL) was added PdCl2(dppf) (58 mg, 0.072 mmol) , and the resulting mixture was heated at 80 for 3 h under a nitrogen atmosphere. The mixture was cooled and filtered. The filtrate was concentrated and the residue was purified by column chromatography on silica gel (0-10MeOH/DCM) to afford the title compound. MS: m/z 260.0 (M + 1) .

As the paragraph descriping shows that 35857-89-7 is playing an increasingly important role.

Reference£º
Patent; MERCK SHARP & DOHME CORP.; COOKE, Andrew J.; PITTS, Daniel; JOHNSON, Adam; BESHORE, Douglas C.; HURZY, Danielle; MITCHELL, Helen; FRALEY, Mark; MCCOMAS, Casey; SCHIRRIPA, Kathy; MERCER, Swati P.; NANDA, Kausik; MENG, Dongfang; WU, Jane; BABAOGLU, Kerim; LI, Chun Sing; MAO, Qinghua; QI, Zhiqi; (156 pag.)WO2016/54807; (2016); A1;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.144294-43-9,3-Amino-5-methylpyridazine,as a common compound, the synthetic route is as follows.

0158-2 A mixture of 6-chloro-N-(5-(2-morpholinoethoxyl)pyridin-3-yl)-1,5-naphthyridine-3-amine (10 mg), 5-methylpyridazine-3-amine (4 mg), tris(dibenzylideneacetone)dipalladium(0) (5 mg), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (10 mg), and cesium carbonate (20 mg) in 1,4-dioxane (1 mL) was stirred at 140 C. for 30 minutes using a microwave reaction apparatus. The reaction mixture was cooled to room temperature, the insolubles were filtered off using celite, and the obtained solution was purified by silica gel column chromatography (methanol-ethyl acetate, NH silica), thereby obtaining N2-(5-methylpyridazin-3-yl)-N7-(5-(2-morpholinoethoxyl)pyridin-3-yl)-1,5-naphthyridine-2,7-diamine (1.9 mg). 1H-NMR(CDCl3/CD3OD=4/1) delta: 8.67 (1H, brs), 8.63 (1H, brs), 8.50 (1H, brs), 8.14 (1H, brs), 8.11 (1H, d, J=9.0 Hz), 7.91 (1H, brs), 7.78 (1H, brs), 7.24 (1H, d, J=9.0 Hz), 7.21 (1H, brs), 4.20 (2H, t, J=5.4 Hz), 3.79-3.71 (4H, m), 2.85 (2H, t, J=5.4 Hz), 2.66-2.56 (4H, m), 2.43 (3H, s). MS m/z (M+H): 459.

The synthetic route of 144294-43-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; FUJIFILM Corporation; FURUYAMA, Hidetomo; KURIHARA, Hideki; TERAO, Takahiro; NAKAGAWA, Daisuke; TANABE, Shintaro; KATO, Takayuki; YAMAMOTO, Masahiko; SEKINE, Shinichiro; MASHIKO, Tomoyuki; INUKI, Shinsuke; UEDA, Satoshi; US2015/322063; (2015); A1;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.5469-70-5,3-Aminopyridazine,as a common compound, the synthetic route is as follows.

General procedure: To a suspension of CDI (106 mg, 0.651 mmol) in THF (10 mL) under nitrogen at roomtemperature was added 11g (200 mg, 0.651mmol). The reaction was stirred at room temperaturefor 10 min and 4-pyridazinamine (61.9 mg, 0.651 mmol) was added dropwise. After refluxed for14 hrs, the mixture was concentrated and water was added. The mixture was then extracted withEtOAc (50 mL*3). The combined organic phases were washed with brine, dried over Na2SO4 andconcentrated. The crude product was then washed with MeOH to give the title compound 7a (95mg, 38%) as a white solid.

5469-70-5 3-Aminopyridazine 230373, apyridazine compound, is more and more widely used in various.

Reference£º
Article; Ding, Xiao; Dai, Xuedong; Long, Kai; Peng, Cheng; Andreotti, Daniele; Bamborough, Paul; Eatherton, Andrew J.; Edge, Colin; Jandu, Karamjit S.; Nichols, Paula L.; Philps, Oliver J.; Stasi, Luigi Piero; Wan, Zehong; Xiang, Jia-Ning; Dong, Kelly; Dossang, Pamela; Ho, Ming-Hsun; Li, Yi; Mensah, Lucy; Guan, Xiaoming; Reith, Alastair D.; Ren, Feng; Bioorganic and Medicinal Chemistry Letters; vol. 27; 17; (2017); p. 4034 – 4038;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.50681-25-9,4-Pyridazinecarboxylic Acid,as a common compound, the synthetic route is as follows.

Intermediate 29 Step A: A solution of pyridazine-4-carboxylic acid (92.5 mg, 0.754) and 2-(7-aza- 1H- benzotriazole-l-yl)-l,l,3,3-tetramethyluronium hexafluorophosphate (283 mg, 0.745 mmol) in 1 : 1 CH2C12/DMF (10 mL) was treated with NEt3 (108 mg, 1.06 mmol) and stirred for 10 min. A solution of 1-28 (224 mg, 0.56 mmol) in 1: 1 CH2C12/DMF (10 mL) was then added and the mixture was stirred for lh (reaction completion monitored by LC/MS). The solvent was evaporated under reduced pressure and the residue was dissolved in CH2CI2 (4 mL), treated with Na2CC>3 (178 mg, 1.68 mmol) and stirred for 3 minutes. The mixture was then purified by column chromatography (MeOH in CH2CI2, 0% to 10%) to afford (R)-tert-buty 3-(7-chloro-6-methoxy-2-(pyridazine-4- carboxamido)-lH-benzo[d]imidazol-l-yl)azepane-l-carboxylate (I-29a). MS calculated for C24H30CIN6O4 (M+H+) 501.19, found 501.2.

The synthetic route of 50681-25-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; IRM LLC; LELAIS, Gerald; EPPLE, Robert; MARSILJE, III, Thomas H.; MICHELLYS, Pierre-Yves; MCNEILL, Matthew H.; LONG, Yun; LU, Wenshuo; CHEN, Bei; BURSULAYA, Badry; JIANG, Songchun; WO2013/184757; (2013); A1;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1837-55-4,3,5-Dichloropyridazine,as a common compound, the synthetic route is as follows.

(1) To a suspension of sodium hydride (483 mg) in THF (40 mL) was added a solution of benzyl alcohol (1.1 g) in THF (5 mL) at 0C under argon atmosphere, and then the reaction mixture was stirred for 15 minutes at room temperature. Subsequently, a solution of the compound 1 (1.5 g) in THF (20 mL) was added dropwise thereto at room temperature followed by stirring for 2 hours. Water was added to the reaction mixture, and the reaction mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated brine, and then dried over anhydrous sodium sulfate. The solvent was distilled off under reduced pressure, and the resultant residue was purified by silica gel column chromatography (eluent: chloroform-ethyl acetate; gradient: 95:5-85:15) to give the compound 2 (776 mg) as a colorless liquid. MS(APCI): 221/223 [M+H]+

As the paragraph descriping shows that 1837-55-4 is playing an increasingly important role.

Reference£º
Patent; Mitsubishi Tanabe Pharma Corporation; SAKAKIBARA, Ryo; USHIROGOCHI, Hideki; SASAKI, Wataru; ONDA, Yuichi; YAMAGUCHI, Minami; AKAHOSHI, Fumihiko; (69 pag.)EP3381904; (2018); A1;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem